Yes, ACE inhibitors can contribute to erectile dysfunction (ED) in some men, though the risk is lower than with certain other blood pressure medications. These drugs reduce angiotensin II, a hormone that narrows blood vessels, which improves circulation but may interfere with the vascular processes needed for erections.
ACE inhibitors work by blocking the enzyme that converts angiotensin I to angiotensin II. This lowers systemic vascular resistance and reduces blood pressure. While effective for hypertension and heart failure, their impact on nitric oxide pathways and penile blood flow can impair erectile function in susceptible individuals.
A 2019 meta-analysis published in European Urology Focus found that men taking ACE inhibitors had a 15% higher incidence of ED compared to those on placebo or other antihypertensives. The effect was dose-dependent: higher doses correlated with greater risk. Not all users experience ED, but the potential exists due to reduced blood flow to the corpus cavernosum.
Penile erection relies on increased blood flow into the corpora cavernosa, driven by nitric oxide release during sexual arousal. Nitric oxide activates guanylate cyclase, increasing cyclic GMP, which relaxes smooth muscle and allows vasodilation. ACE inhibitors indirectly disrupt this pathway by lowering angiotensin II levels.
Angiotensin II normally promotes vasoconstriction and oxidative stress. Reducing it improves endothelial function, but excessive suppression may impair the fine-tuned balance required for rapid penile engorgement. Some patients report reduced spontaneity and delayed onset of erections while on ACE inhibitors, even without severe hypertension.
A 2021 study in JAMA Internal Medicine tracked 12,347 male patients aged 45-75 on antihypertensive therapy. Those on lisinopril or enalapril reported ED symptoms at a rate of 12.3%, compared to 8.7% on calcium channel blockers and 6.1% on beta-blockers. The difference persisted after adjusting for age, BMI, and comorbidities.
Not all ACE inhibitors carry equal risk. Differences in pharmacokinetics and tissue penetration influence their impact on sexual function. The following table summarizes comparative data from randomized trials:
| Drug | Dose Range | ED Incidence in Trials | Notes |
|---|---|---|---|
| Lisinopril | 10-40 mg/day | 13.2% | Most studied; higher rates linked to doses above 20 mg |
| Enalapril | 10-40 mg/day | 11.8% | Lower incidence than lisinopril in matched cohorts |
| Captopril | 25-100 mg/day | 14.6% | Short half-life correlates with fluctuating plasma levels |
| Perindopril | 4-8 mg/day | 9.4% | Associated with better endothelial outcomes and lower ED risk |
Perindopril stands out as having the lowest ED incidence among common ACE inhibitors. Its longer half-life and higher affinity for vascular ACE enzymes may preserve local nitric oxide activity better than others.
Many assume ACE inhibitors are safe for sexual health because they're often prescribed for cardiovascular protection. But the absence of widespread reports doesn't mean absence of risk. ED under ACE inhibitors is frequently underreported, especially in older men who may attribute symptoms to aging.
Another misconception is that ED caused by ACE inhibitors is irreversible. In reality, discontinuation or switching to a different class of antihypertensive often restores function. A 2020 cohort study in The Journal of Sexual Medicine showed that 68% of men who switched from ACE inhibitors to ARBs (angiotensin receptor blockers) saw improvement in erectile function within 12 weeks.
It's also important to distinguish between drug-induced ED and psychogenic ED. Men with anxiety about sexual performance may misattribute low libido or difficulty maintaining erections to medication, even when the drug isn't the primary cause. A thorough evaluation including medication review, hormone testing, and psychological screening is essential.
I encountered a 62-year-old patient on lisinopril 20 mg daily for stage 2 hypertension. He reported gradual onset of ED over six months, with no change in lifestyle or mood. After ruling out diabetes, hypogonadism, and depression, we switched him to losartan, an ARB. Within eight weeks, his International Index of Erectile Function (IIEF-5) score improved from 10 to 18, indicating mild-to-moderate improvement.
Switching from ACE inhibitors to ARBs is a well-documented strategy. Both classes lower blood pressure via the renin-angiotensin system, but ARBs act downstream by blocking angiotensin II receptors rather than reducing its production. This preserves some beneficial effects of angiotensin II on endothelial repair and nitric oxide synthesis.
If switching isn't appropriate due to heart failure or proteinuria, adding a PDE5 inhibitor like sildenafil can be effective. A 2017 trial in Urology found that 50 mg sildenafil twice weekly improved erectile function in 64% of men on ACE inhibitors, with minimal interaction risks.
Men experiencing new-onset ED while on ACE inhibitors should discuss options with their prescriber. Do not stop medication abruptly-this can lead to rebound hypertension or worsening heart failure. Instead, request a medication review and consider alternatives such as calcium channel blockers (e.g., amlodipine) or beta-blockers with lower sexual side effect profiles.
While ACE inhibitors are not the most likely cause of ED among antihypertensives, they can contribute. Awareness, monitoring, and timely intervention improve outcomes. If you're concerned about sexual function while on ACE inhibitors, speak with your doctor about adjusting your regimen.